• Significant drought has long been recognized as a major climactic concern as some of the earth’s populations struggle to ensure they have sufficient water
• Amid drought conditions currently raging in Mexico City, some residents have signed an MOU with green tech engineering services company Energy and Water Development Corp. to harvest water directly from the atmosphere using EAWD’s patent-pending technology
• The planned water generation facility is expected to produce about 3.2 million liters of water annually, with expectations of adding millions more in later building phases
• The facility is a technological leap over traditional dry area water-collecting methods, where residents spread sheets to draw humidity off fog clouds, a method used in places such as the Atacama Desert, where rain has not fallen in some places during the past 400 years

Concerns about climate change have grown in recent years as scientists raise warnings about shifts in the world’s biomes, but one climate concern that is not new is the presence of drought conditions in select parts of the planet.

Science fiction has long envisioned the idea of harvesting water from the air as a solution to drought, whether through the “windtraps” of the Dune series in the 1960s, or Luke Skywalker’s moisture farm in the original Star Wars of the 1970s.

Now, Florida-based green tech engineering services company Energy and Water Development (OTCQB: EAWD) is putting the idea of harvesting drinking water from the atmosphere into real world application. Working with governmental institutions as well as NGOs (non-governmental organizations), the company is using its own patent-pending technology design to come up with energy and water solutions in areas where they are in short supply.

“Energy and Water Development Corp. is a leading engineering company that is focused on the innovation of the generation of sustainable water and energy supply. We … put together state-of-the-art technologies that will allow (us) to secure the provision of water and energy in any kind of situations in any part of the world,” company CEO Irma Velazquez said during an interview with The Harvest Podcast (https://ibn.fm/wgO5i). The podcast is a series that turns the spotlight on thought leaders, experts and breakthrough companies who make “disruptive and impactful contributions to society through groundbreaking initiatives” (https://ibn.fm/oHrT3).

“When you talk about water supply, you see that the challenge is about the geopolitical situation, the infrastructure, in general,” Velazquez said. “(Our) main objective is to be an evolving company that goes and works with innovation … and helps those who need projects onsite that (will) be sustainable in response to the new demands of the circumstances in climate change.”

The idea of extracting water from the air has been put into practice in other locations with far less developed resources. In Chile’s famed Atacama Desert, regarded as one of the driest places on earth where, in some parts, rain has not fallen for hundreds of years, Chileans have learned to harvest water from fog that comes inland from the ocean by “putting up plastic sheets with pans underneath. The fog collects on the plastic and drips into the pans, giving the people water for crops and drinking” (https://ibn.fm/LYKh2).

EAWD’s solutions to tackling water scarcity and energy challenges represent a self-sufficient energy supply Atmosphere Water Generation system and Off-grid EV Charging stations. The Off-Grid Atmosphere Water Generation Plant is at the heart of a joint memorandum of understanding (“MOU”) EAWD signed in December with residents in a municipality of Mexico City where drought conditions are leaving residents of one of the world’s largest cities at risk of running entirely out of water before the rainy season begins in the fall (https://ibn.fm/lgqOu).

Under the agreement, EAWD will deploy its water generation plant in a 5,000-square-meter facility that is expected to produce approximately 3.2 million liters of water annually by extracting moisture directly from the air. Although those figures are an average, it’s a bit like turning on a water tap in the desert that runs 24 hours a day, every day. Additional phases are planned to then increase the size of the facility to produce millions more liters of water than the original plant.

For more information, visit the company’s website at www.Energy-Water.com.

NOTE TO INVESTORS: The latest news and updates relating to EAWD are available in the company’s newsroom at http://ibn.fm/EAWD

• Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2
• GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8%
• Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent announcement of an applied research program to evaluate certain molecular characteristics of its patented DehydraTECH(TM) processed GLP-1 drug, semaglutide, related to its mode of action and performance. It also marks a significant milestone in the company’s 2024 research pipeline (https://ibn.fm/ilW5r).

At the beginning of the year, the company resolved to focus on GLP-1 studies for the calendar year, having shown positive results in an 8-week clinical study in 2023/24. This latest milestone followed its recent contract award and independent ethics review board approval in April.

The study will spot three arms, comparing 7 mg semaglutide dose formulations. The first arm used a positive control Rybelsus(R) swallowed tablet, while the second arm – due to be performed in late June – will feature DehydraTECH-semaglutide swallowed capsules. Nearly 5 weeks are required between doses to “wash-out” lingering quantities of drugs between study arms.

The last arm will, for the first time, utilize an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. This study arm will investigate whether DehydraTECH-enhanced semaglutide can be absorbed at any level systemically through the sublingual/buccal tissues of the mouth and throat, and into the bloodstream, with fewer side effects than from swallowed pill administration. It will mostly avoid the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in exceptionally low blood absorption rates.

GLP-1 exhibits poor oral bioavailability, usually as little as 0.8%, despite having demonstrated the ability to address diabetes and weight loss. Lexaria, through its DehydraTECH technology, has proven to significantly improve this bioavailability.

Lexaria looks to follow through with this clinical study, and more, ultimately carving out a significant market share in the diabetes treatment market, projected to reach $134.1 billion by 2030. Its management is optimistic that this will be its biggest year yet, where all its efforts and investments will pay off.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/nhPpb).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SuperCom, a global leading provider of traditional and digital identity solutions, is tapping into the growing use cases for electronic monitoring (“EM”) solutions globally
• New adoption of the technology is seen in a move by the U.S. government to use ankle monitors to also track asylum seekers entering the country to help support and expedite their asylum process
• For SuperCom, this is a further validation of the value of EM solutions, their versatility and overall effectiveness
• SuperCom’s management anticipates a growth in the demand for its products as the conversation around these solutions continues to proliferate

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, is steadily advancing its technologies, primarily given the growing use case for electronic monitoring (“EM”) solutions globally. This stems from a deep understanding of the current global market for such solutions, which goes beyond only offender monitoring and also now covers tracking for migrant families seeking asylum in the U.S. The goal is to keep asylum seekers from skipping out on their required asylum hearings.

In previous administrations in the U.S., there was a push for the detainment of families in Immigration and Customs Enforcement (“ICE”) facilities, a move that faced backlash. In addition, scientific studies showed that detaining minors, even with their parents, could cause developmental damage. The public outcry prompted the current administration to explore better approaches to tackling the issue (https://ibn.fm/if4xs).

The U.S. government has been transitioning from family detention to adopting ankle bracelets and traceable cell phones. This laid the foundation for the new program, which leverages electronic monitoring technology while using curfews and expedited asylum screenings. In an article published by The New York Times, it was noted that this was in response to the growing migrant situation, with the country having recorded over 2.5 million migrant encounters at the southwest land border in the 2023 fiscal year alone.

The U.S. government’s adoption of EM within ICE has been geared toward keeping track of thousands of migrants and making rulings in a make-or-break step of the asylum process. SuperCom sees this move as further validation of the overall effectiveness, viability, and dependability of EM solutions. It also presents new opportunities that other governments worldwide can leverage to expedite huddles in their legal processes and track and hold accountable specific persons of interest.

SuperCom has made a name for itself by offering superior EM solutions and a whole suite to support them. With a focus on offenders of domestic violence, the company has proven itself on many occasions and in different countries globally, affirming the value of its products and services and the overall viability of EM solutions.

As the conversation about these solutions continues to proliferate, SuperCom anticipates potential growth in the demand for its products. In addition, as the solutions find their way into other application areas beyond offender monitoring, as is the case with the U.S. immigration program, the company anticipates that its offerings can address even more potential use cases.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, just acquired additional contiguous claims at its flagship Kenbridge Nickel Project
• This brings the total coverage to 4,273 ha, with 93 contiguous patents, four mining licenses, and 153 single-cell mining claims
• The company also announced the commencement of the 2024 baseline field work conducted by Aspen Biological Ltd.
• These two milestones are a testament to the company’s commitment to creating shareholder value and following through with its plans for the 2024 calendar year

Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral and battery materials exploration and mining development company, just announced its acquisition of additional contiguous claims at the Kenbridge Nickel Project, located in Northwestern Ontario. This brings the total coverage to 4,273 ha, with 93 contiguous patents, four mining licenses, and 153 single-cell mining claims (https://ibn.fm/7MZ6D).

Earlier in the year, Tartisan’s management reiterated its plan to bank on the Kenbridge Nickel project to carve out a significant market share in the global nickel mining market. Given its potential and overall value, this flagship project is integral to the company realizing its commitment to creating shareholder value. The acquisition of additional contiguous claims points to the management’s confidence in the property and its potential to help Tartisan tap into a market projected to be valued at over $84.04 billion by 2030.

Tartisan also announced the commencement of the 2024 baseline study field work conducted by Aspen Biological Ltd., led by its principal, Lindsay Spenceley (H.B.Sc-Biology), a biologist with 23 years of professional experience. The study includes baseline aquatic and terrestrial field work within the project footprint and access roads. Results from these studies will develop baseline environmental reports to support provincial and federal reviews, approvals, and permitting for advanced exploration and eventual mine development.

Mr. Spenceley will lend her years of experience carrying out monitoring programs for boreal caribou, wolverine, SAR bat species, and eastern whip-poor-will. This will be integral in fast-tracking the company’s property utilization while working toward the timelines detailed earlier in the year.

“In addition to excellent field skills in all seasons and environments, Lindsay has considerable project management skills. Aspen Biological can leverage its network of experienced resource professionals to pull together, as needed, multi-disciplinary teams to deliver upon project requirements and timelines in a cost-effective manner,” noted Mark Appleby, Tartisan’s CEO.

With the acquisition of additional claims and the commencement of the 2024 baseline study field work, Tartisan is on track with projects for the current calendar year. These milestones are a testament to the company’s commitment to creating shareholder value and following through with its plan to double down on its Flagship Kenbridge Nickel Project.

For more information, visit the company’s website at www.TartisanNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to TTSRF are available in the company’s newsroom at https://ibn.fm/TTSRF

• Preliminary interpretation of initial MLEM survey results indicates new exploration targets highlighting excellent potential to discover additional copper mineralization
• Copper process projected to continue upward trend
• Results open “a whole new space for potential discovery,” says Aston Bay CEO

As copper prices climb to a 2024 high, Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) is reporting initial results from geophysical activities that are currently underway at its Nunavut-based Storm Copper Project (https://ibn.fm/d5faa). According to the report, preliminary interpretation of the initial moving loop electromagnetic (“MLEM”) survey results indicates several new exploration targets highlighting excellent potential to discover additional copper mineralization.

“Soaring copper prices show no signs of slowing down, analysts say, with the red metal’s rally fueled by supply risks and improving demand prospects for energy transition metals,” states a recent CNBC report (https://ibn.fm/dkBta). “Copper prices with May delivery traded at $4.323 per pound in New York as of Wednesday morning, extending gains after settling at its highest level since June 2022 in the previous session.

“Three-month copper prices on the London Metal Exchange traded 0.6% higher at $9,477 per metric ton,” the report continued. “Demand for copper is widely considered a proxy for economic health. The base metal is critically important to the energy-transition ecosystem and is integral to manufacturing electric vehicles, power grids and wind turbines. Wall Street banks are bullish on the outlook for copper prices through to the end of the year.”

With this backdrop, the results from Aston Bay regarding its Storm Copper Project, which is located on Somerset Island in Nunavut, are particularly promising. The program is fully funded and is being conducted by American West Metals Limited, which has completed the required expenditures to earn an undivided 80% interest in the project.

According to the report, initial MLEM data shows that the high-grade copper mineralization at the Cyclone Zone likely extends in most directions. In addition, new EM anomalies have also been identified over 1,000 meters along strike from the Chinook Zone as well as in the areas of the 2023 discoveries at the Thunder, Lightning Ridge and Gap Prospects. These results, the company observes, indicate strong potential for extensions to known high-grade copper mineralization.

The company also reported that the MLEM surveys continue in the Storm area, with plans to move south toward the Blizzard and Tornado Prospects. In addition, deeper-looking MLEM surveys are also planned between the North and South Graben Faults in the Storm area. The company noted that track-mounted reverse-circulation (“RC”) drilling is underway, with one drill currently operating and a second drill being deployed to the site. This drilling is designed to test the new targets along with several historical EM anomalies and other high-priority targets for near-surface, high-grade copper mineralization.

“It is very encouraging to see geophysics identify new targets at Storm,” said Aston Bay CEO Thomas Ullrich. “Moving Loop EM anomalies have demonstrated a very strong correlation with high-grade copper mineralization, so these are high-priority drill targets. This initial phase of geophysics is designed to be effective in the shallow subsurface, less than 200 metres depth, well within reach of the RC drill rigs on site. The ongoing drilling will aim to test these targets in the coming weeks and over the summer program.”

Ullrich noted that the planned deep-penetrating, wider-spaced MLEM survey will explore the Storm Central Graben area below the known mineralization with a targeted search space of 200 to 500 meters in depth. “This opens a whole new space for potential discovery,” he continued. “In the 2024 season, we intersected copper mineralization at these depths with the same mineralogy as seen at the surface. We anticipate these deeper-looking surveys will enhance our drill targeting for potentially thicker and more laterally extensive zones of mineralization in this very prospective but underexplored zone.”

Aston Bay is a publicly traded mineral exploration company exploring for high-grade copper and gold deposits in the state of Virginia and in Nunavut, Canada. The company is led by CEO Thomas Ullrich with exploration in Virginia directed by the company’s advisor, Don Taylor, the 2018 Thayer Lindsley Award winner for his discovery of the Taylor Pb-Zn-Ag Deposit in Arizona.

The company and its joint venture partners—American West Metals Limited and its wholly-owned subsidiary, Tornado Metals Ltd.—have agreed to form a 20/80 unincorporated joint venture and enter into a joint-venture agreement regarding the Storm Project property, which also hosts the Seal Zinc Deposit. Under such agreement, Aston Bay shall have a free carried interest until American West has decided to mine upon completion of a bankable feasibility study, meaning American West will be solely responsible for funding the joint venture until such decision is made. After such decision is made, Aston Bay will be diluted in the event it does not elect to contribute its proportionate share, and its interest in the Storm Project property will be converted into a 2% net smelter returns royalty if its interest is diluted to below 10%.

For more information, visit the company’s website at https://AstonBayHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ATBHF are available in the company’s newsroom at https://ibn.fm/ATBHF

• Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference
• CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization
• The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently participated in three investor conferences during May – The Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. These conferences provided Clene with the opportunity to present its lead drug candidate CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization.

The Mizuho Neuroscience Summit 2024 took take place on May 20-21 at the Boston Harbor Hotel in Boston, MA (https://ibn.fm/yVw8Y). This event, organized by Mizuho Americas, is part of their initiative to explore promising investment trends and breakthroughs in the field of neuroscience. The summit included panel presentations and opportunities for one-on-one meetings, providing a platform for leading medical experts and biopharmaceutical companies to discuss advancements in treating neurodegenerative and psychiatric diseases​.

The inaugural summit in 2023 focused on key topics such as Alzheimer’s disease treatment, neurodegenerative diseases, and emerging psychiatric treatments, featuring insights from top venture capital investors and biotech markets. This kind of event is crucial as it brings together expertise from various areas of neuroscience to foster discussions that could lead to new collaborations and innovations in the field​.

The Benchmark 2024 Healthcare House Call Virtual Conference occurred May 21-22, 2024 (https://ibn.fm/nsz6r). This virtual event was designed to facilitate one-on-one meetings between participants, offering a direct and personalized way to engage with healthcare experts and professionals. The format of this conference supports in-depth discussions and networking opportunities in a virtual setting, making it accessible for a wide audience regardless of geographic location. This event is part of a broader series of conferences that focus on the healthcare sector, providing insights and updates on various healthcare topics and trends.

The Virtual A.G.P. Healthcare Conference took place May 22, 2024 (https://ibn.fm/pkTaR). This conference was set up as a virtual event, providing a platform for participants to engage in one-on-one meetings with healthcare professionals, investors, and industry experts. The virtual format of this conference is particularly designed to cater to a global audience, enabling stakeholders from various parts of the world to connect, share insights, and discuss the latest trends and developments in the healthcare sector without the need for travel​.

The company’s presentation about CNM-Au8 showcased it as an innovative treatment involving a suspension of gold nanocrystals aimed at addressing neurodegeneration. It works by targeting the core issues prevalent in diseases like ALS, MS, and Parkinson’s—specifically mitochondrial dysfunction, NAD+ decline, and oxidative stress. Its catalytic action helps maintain cell metabolism, reduce harmful reactive oxygen species, and promote protein homeostasis, thereby offering neuroprotective and remyelinating benefits.

The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported. This highlights its potential as a safe adjunct to other treatments, enhancing cell function and survival, particularly noted in clinical ALS trials.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region
• PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies
• PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide resources to ensure a steady supply of suramin to endemic regions

PaxMedica (NASDAQ: PXMD), a biopharmaceutical firm dedicated to advancing treatments for neurological disorders, recently announced that it has received an urgent plea from the Ministry of Health (“MOH”) of Malawi. The MOH is requesting emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region (https://ibn.fm/wWNpQ).

Following the recent completion of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin), PaxMedica has promptly brought this urgent request to the attention of the U.S. Food and Drug Administration (“FDA”). The company aims to assess any potential impact on its ongoing development program and plans for submitting a New Drug Application (“NDA”) for PAX-101. PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, commonly called “sleeping sickness”, transmitted by tsetse flies.

Howard Weisman, Chairman and CEO of PaxMedica, emphasized the significance of the MOH’s request, highlighting the critical situation faced by countries vulnerable to the fatal disease TBr HAT. He underscored the continued necessity of suramin as the standard treatment for Stage 1 of the infection, particularly citing the Malawi dosing protocol used for nearly a century to save lives in the region.

Weisman also noted the potential public health benefit of having multiple global manufacturers of drugs like suramin, as it could create diverse supply chains and ensure a steady drug supply. PaxMedica’s Real World retrospective evidence, including the HAT-301 clinical study of TBR HAT patients treated with suramin between 2000 and 2020, involved a significant number of cases from Malawi. This underscores the importance of Malawi’s contribution to PaxMedica’s research efforts on PAX-101.

PaxMedica is actively engaging with regulatory authorities in the U.S. and Malawi to address the emergency request from the Malawi Ministry of Health. Additionally, the company is collaborating with the FDA to determine the optimal path for submitting the PAX-101 NDA for regulatory approval. PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide resources to ensure a steady supply of suramin to endemic regions.

Wiseman also said [that the] “FDA has agreed that having more than one global manufacturer of drugs like suramin could provide public health benefit by creating multiple supply chains and would help ensure a steady supply of the drug product.”

The most recent Bell2Bell Podcast sheds light on PaxMedica’s commitment to addressing the critical storage of medications required to combat the life-threatening sleeping sickness crisis in Malawi. The podcast features PaxMedica’s CEO and Malawi Health Official, Dr. Marshal Lemerani, discussing the urgency of the request made for suramin with host Stuart Smith. The full podcast can be found at https://ibn.fm/VgbgO.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• The 5th Annual Reg A & Crowdfunding Conference will take place at New York’s luxurious Westchester Country Club on June 20
• The fifth annual conference will play host to investors, entrepreneurs and financiers as we to delve into the latest trends within the equity capital markets industry
• This year’s conference will feature a number of keynote presentations and speakers, including on topics such as the structuring and efficient marketing of Reg A+ and Crowdfunding deals

Learn from (and network with) experts who raise capital with these powerful tools

Equity capital markets have long been an attractive source of growth capital for companies seeking to finance further expansion, particularly in a scenario where debt financing has grown increasingly expensive to obtain. A dynamic landscape of equity crowdfunding avenues has emerged to respond to this capital requirement, with entrepreneurs seeking increasingly innovate manners through which to access capital, matching their needs with investors seeking opportunities for growth. Introduced through the 2012 JOBS Act, Regulation A+ (Reg A+) funding has emerged as one of the fastest growing funding mechanisms for emerging companies today. Permitting companies to gain exposure and raise up to $75 million annually through the sale of securities to both, accredited and non-accredited investors, the emergence of Reg A+ equity capital raises has further democratized access to potential returns.

From 2021-2022 period, Reg A+ issuers raised $1.8 billion through a wide array of qualifying offerings. The process of accessing this funding avenue has historically been complex. A lengthy process required to gain SEC qualification, coupled with the difficulty in carrying out a successful marketing campaign needed to attract investors has been a constraint for some companies seeking to raise assets through Reg A. However, companies that are able to navigate the regulatory process and execute solid marketing campaigns have raised significant capital while avoiding many of the pitfalls associated with traditional capital-raise tools.

The upcoming Reg A & Crowdfunding Conference has been designed to provide prospective corporate issuers and financiers with a venue to come together to help facilitate the regulatory hurdles and obstacles traditionally associated with these capital raise methods.

If you are the executive of a private company thinking about a Reg A or Crowdfunding campaign, you may be eligible for a free ticket to the conference. Learn more.

With over 21 years of experience and having hosted more than 200 conferences, seminars and webcasts on a variety of financial topics, DealFlow Events is uniquely prepared to deliver the actionable information you need at the 5th Annual Reg A & Crowdfunding Conference at New York’s Westchester Country Club on June 20.

This is the largest annual conference of its kind, bringing together a broad array of online investment platforms, brokers, legal and financial advisors, investors and other dealmakers involved within the space. The Reg A & Crowdfunding Conference has also historically been a must-attend event for hundreds of private and public companies seeking to raise capital. 

The 2024 Conference expands further with an increased focus on online deal-marketing tactics. Attendees will glean insights from experts on deal structures, fees and expenses, as well as the continuously evolving regulatory landscape.

This year’s conference will touch upon a range of topics, including an overview on the current environment for raising capital through Reg A and Crowdfunding deals, why Crowdfunding has been an attractive fundraising avenue when venture debt and business loans have not been an option, how to determine whether to pursue a Reg A or Crowdfunding campaign, and how to increase the visibility and marketing of a Reg A and Crowdfunding offering in the current financial climate.

Both of these options offer the potential for a faster capital raise at far lower expense than a traditional IPO.

Register now while seats are still available. This event routinely reaches capacity. We look forward to seeing you soon at The Westchester Country Club.

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking.

Specific areas of discussion will include:

• Targets for novel drug development
• Toxicology studies and considerations
• The dosage debate and new evidence
• Second generation psychedelic drug design
• FDA regulatory guidance

The speaker panel consists of an impressive line-up of leaders and dignitaries who will share important insights and strategies on a number of industry topics. This includes the latest discoveries, psychedelic therapeutics, and clinical trials, offering a fresh perspective and critical knowledge to attendees.

Speaker topics will cover:

• Clinical Trial Design
• Legal Issues
• Intellectual Property
• Regulatory Guidance
• Psychedelic Drug Delivery
• Commercialization
• Emerging Preclinical Science
• New Clinical Data

This conference offers an excellent forum for newcomers as well as veterans for the discovery and exchange of knowledge in the world of psychedelics and therapeutics.

The event commences with opening remarks from the chairperson, Peter Hendricks, Ph.D., Professor, Department of Psychiatry, University of Alabama Birmingham. Attendees will get answers to some vital issues related to ways of optimizing psychedelic trials and scaling trail delivery while still being consistent. Other important topics include discussions on studies being conducted for the treatment of Schizophrenia, postpartum depression, distress in cancer, and more.

After the morning refreshment break, the conference will resume with a panel discussion navigating the challenges in research and compliance with the Federal Analogue Act.

The conference is being held at the luxurious Revere Hotel Boston Common, 200 Stuart Street, Boston, MA (www.reverehotel.com), described as “Shaped by local culture and the rebellious, independent spirit of Boston, Revere Hotel Boston Common is a downtown refuge for the adventurous and curious. Immerse yourself in authentic local experiences at our original Back Bay hotel, located steps from Boston’s Theater District, Newbury Street and Copley Square.”  

To register and learn more, please visit https://ibn.fm/FCMNc.

DGE invites medical affairs and healthcare professionals to attend the 8th Digital Strategy & Innovation For Medical Affairs summit in Philadelphia on June 5-6, 2024. Experts attending the conference will offer insights to leverage digital technology for building patient and caregiver relationships, and for maintaining market position.

The summit is organized by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotechnology, healthcare, medical devices, and allied industries.

The event agenda covers:

• Incorporating AI into patient outreach
• Identifying the most important tools needed to create a digital engagement medical affairs strategy
• Crafting medical animation for enriching HCP initiatives
• Using digital technologies to monitor and analyze the patient voice
• Increasing engagement and reach by including digital leaders in the company’s digital marketing journey

The event focuses on discovering and discussing new methods of digital engagement. Experts conducting speaker sessions will speak about developing the right vendor and data management relationships, and also about training medical teams with the latest digital technologies to increase patient engagement for future success.

Attendees of DGE events enjoy a multitude of benefits such as targeted networking as well as access to presentations after the event. The summit offers a phenomenal opportunity to learn about the latest trends and strategies for digital transformation. Professionals and executives get to showcase their services and business ideas on a prestigious conference platform attended by the eminent leaders of the industry.

To learn more, please visit https://ibn.fm/PvsSS.